Company Registry

B-MOGEN Biotechnologies Inc
Profile last edited on: 9/13/2019

Custom tools for gene delivery and gene editing
Year Founded
First SBIR Year
Latest SBIR Award
Program Status
Active (Acquired)


Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1621 East Hennepin Avenue Suite B-15
Minneapolis, MN 55414
   (612) 309-7653
Multiple Locations:   
Congressional District:   05
County:   Hennepin

Public Profile

In June 2019 it was announced that Bio-Techne Corporation (NASDAQ: TECH) - with a track record of several small firm acquisitions - had reached agreement to acquire all of the stock of B-MoGen Biotechnologies Inc . B-Mogen is a four-year old University of Minnesota genome engineering startup start-up already having grown to some 20 employees. Working on the most complex gene editing problems with proprietary, cutting edge gene editing and delivery tools, B-Mogen is enabling and accelerating growth in immunotherapy treatments utilizing cutting edge gene editing and gene delivery technologies to create unique research solutions and disease models in human cell. The firm has several SBIR awards already taken and underway and has entered into strategic partnerships with biotechnology companies, completed projects for clients in academia and industry, along with having successfully licensed and developed novel intellectual property focused on genome engineering.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Jeff Liter -- President and CEO

  Anindya Bagchi -- Founder

  Lampi Hermanson --

  Leah Hogdal --

  David L Lampi Hermanson --

  Branden S Moriarity -- Chief Scientific Officer

  Neil Otto --

  Kristin Taylor Geisler -- Chief Financial Officer

  Beau R Webber -- Director of Stem Cell Technologies

SBIR firms in the news

There are no news available.